Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2011

Department of Defense Backs Two Lupus Projects with $2.3M

  • The U.S. Department of Defense (DoD) is separately granting two researchers $2.3 million to advance their respective lupus research. The money comes from DoD’s Congressionally Directed Peer Reviewed Medical Research Program (PRMRP).

    I-Cheng Ho, M.D., Ph.D., associate physician at Brigham and Women’s Hospital, received $1.2 million. The work will examine a protein called Ets1 to determine if it can counteract the disease process of lupus; it is believed that the function of Ets1 may be impaired in people with lupus.

    Trine Jorgensen, Ph.D., assistant staff, department of immunology, Cleveland Clinic Foundation was awarded $1.1 million. The research will study why females are disproportionately affected by lupus; nine out of ten people with lupus are reportedly female. Dr. Jorgensen’s studies will explore the role of a population of immunosuppressive cells in the development of lupus and analyze related mechanisms of disease suppression as it may occur in males.

    To date, $11.8 million has reportedly been awarded to lupus researchers through the PRMRP. Due to the changing demographics of the military population, there is an ever-increasing prevalence of lupus in military.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »